CNS Therapeutics - A World Market Review

NEW YORK, Jan. 29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

CNS Therapeutics - A World Market Review

http://www.reportlinker.com/p0164268/CNS-Therapeutics---A-World-Market-Review.html

While the available CNS therapies can slow down deteriorating condition of patient, the clinical pipeline boasts of new drug classes with potential to stop or reverse the disease's progression. Continuing switch over of patients from typical or traditional anti-psychotics to expensive and safer atypical anti-psychotics drugs, such as Zyprexa, Risperdal and Geodon is driving the market forward. Global market for anti-depressants, a dominant product category of CNS therapeutics is on a decline, succumbed by increasing generic competition, loss of patent protection of key drugs, and increased risk of suicidal tendencies among adolescents.

These and other market data and trends are presented in "CNS Therapeutics: World Market Review" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses

CNS THERAPEUTICS BMR-1068

CONTENTS

1. METHODOLOGY 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Quantitative Techniques & Reporting Level 3

2. GLOBAL MARKET OVERVIEW AND OUTLOOK 4

Factors Influencing Demand 4

The 'Age Factor' 4

Role of Diagnostic Techniques 4

Increasing Disease Awareness 4

Emergent Technologies 4

Reimbursement Policies 5

Outlook 5

Market Trends and Issues 5

Booming Therapeutic Opportunities for Neuro-Degenerative

Disorders 5

Spur in CNS Drug Delivery Technologies 6

Migraine Market Offers Growth Opportunities to Prophylaxis

Products 7

Demand for Therapeutic Peptides Spurred by Dearth of

Effective Therapies 7

Anti-Depressants 7

Major Trends in the Depression Market 8

SSRIs are the Preferred Choice Despite Side Effects 8

Attention Deficit Hyperactivity Disorder (ADHD) 9

Major Trends in the ADHD Market 9

Anti-Psychotics Market 10

Restrictions on Promotion Hamper Market Prospects 10

Insomnia 11

Anti-Insomnia Drugs from Corporate Giants Flood the Sleep

Market 11

Neuropathic Pain 11

Patent Expiry of Leading CNS Drugs: 2005-2017 12

3. PRODUCT FACTS 13

CNS Disorders 13

A. Anti-Alzheimer's Drugs 13

B. Anti-Parkinson's Drugs 13

C. Anti-Epilepsy Drugs 14

D. Pain Management Drugs 14

E. Anti-Psychotics Drugs 14

(i) Bipolar disorder 14

(ii) Schizophrenia 14

F. Anti-Depressants Drugs 15

G. Others 15

(i) Attention Deficit Hyperactivity Disorder 15

(ii) Multiple Sclerosis 16

(iii) Insomnia 16

(iv) Restless Legs Syndrome 16

(v) Anxiety 17

4. CORPORATE DEVELOPMENTS 18

P1vital Creates Global Consortium to Develop CNS Experimental

Medicine 18

Neurobiological Tech Teams Up with Buck Institute 18

ExonHit Therapeutics and Allergan Ink Contract to Develop CNS

Agents 18

NeuroSearch Commences Clinical Phase I study with NSD-788 in

France 18

Abilify® Meets CHMP Standards 18

UCB Receives Recommendation for Approval for Neupro® 19

Schering-Plough Acquires Organon 19

UCB Launches Neupro® in the US 19

GlaxoSmithKline Forms Alliance with Targacept 19

GSK Teams-Up with Sepracor for Commercializing Lunivia® 20

US FDA Rebut NDA for bifeprunox 20

Medtronic and Alnylam Extend their Drug- Device Collaboration 20

Neuren Takes Over Hamilton 20

Roche Forms Partnership with Synosis Therapeutics to Evaluate

Five CNS Compounds 20

NeuroSearch Starts Clinical Phase I Study with ACR343 in Sweden 21

Lundbeck to Promote Circadin® in Europe 21

Sepracor Inks Partnership with Eisai to Develop and Market 21

Lunesta® in Japan 21

5. MAJOR PLAYERS 21

Abbott Laboratories (USA) 21

Alkermes, Inc. (USA) 22

AstraZeneca Plc (UK) 22

Boehringer Ingelheim GmbH (Germany) 22

Bristol-Myers Squibb (USA) 22

Cephalon, Inc. (USA) 23

Dainippon Sumitomo Pharma Co., Ltd. (Japan) 23

Elan Corporation Plc (Ireland) 23

Eli Lilly and Co. (USA) 23

Fabre-Kramer Pharmaceuticals, Inc. (USA) 24

F. Hoffmann-La Roche Ltd. (Switzerland) 24

Forest Laboratories, Inc. (USA) 24

GlaxoSmithKline (UK) 24

H. Lundbeck A/S (Denmark) 24

Johnson & Johnson (USA) 25

Janssen Pharmaceutica N.V. (Belgium) 25

Janssen-Cilag (Switzerland) 25

Merck & Co., Inc. (USA) 25

Neurocrine Biosciences, Inc. (USA) 25

Novartis AG (Switzerland) 25

Sandoz International GmbH (Germany) 26

Organon N.V. (The Netherlands) 26

Ortho-McNeil Neurologics, Inc. (USA) 26

Otsuka Pharmaceutical Co., Ltd. (Japan) 26

Pfizer, Inc. (USA) 27

Sanofi-Aventis (France) 27

Schwarz Pharma AG (Germany) 27

Sepracor, Inc. (USA) 27

Shire Plc (UK) 27

Solvay Pharmaceuticals S.A. (Belgium) 28

Takeda Pharmaceutical Co., Ltd. (Japan) 28

Teva Pharmaceutical Industries Ltd. (Israel) 28

UCB S.A. (Belgium) 28

Wyeth (USA) 29

6. GLOBAL MARKET ANALYTICS 29

7. THE UNITED STATES 37

Cost Implications of CNS Disorders 37

Alzheimer's Market 38

Anti-Alzheimer's Drugs Approved for Use in the Past 38

Cost of Care to AD Patient 39

Clinical Pipeline 39

Anti-Psychotics 39

Growth Dampeners 39

Clinical Pipeline 40

Antidepressants 41

Antidepressants to Feature Black-Box Warnings 41

Antidepressant Consumption Falls Among Children and Adolescents 41

Multiple Sclerosis 42

Insomnia Market 42

Rising Consumption of ADHD Drugs Combat Safety Concerns 42

Unmet Medical Needs in Neuropathic Pain Offer Growth Prospects 43

CNS Tuberculosis Raises its Ugly Head 43

8. CANADA 45

Facts & Figures 45

9. EUROPE 47

a. France 51

b. Germany 52

c. Italy 54

d. The United Kingdom 56

e. Spain 58

f. Rest of Europe 59

10. ASIA-PACIFIC 62

An Overview of the Japanese Market 62

Pain Management Market 62

11. LATIN AMERICA 64

12. REST OF WORLD 65

EXHIBITS

Table 1: Sales of Leading ADHD Drug Brands in the World - 2005

(In US$M)

Table 2: Sales of Leading Atypical Anti- Psychotic Drug Brands

in the World - 2005 (In US$ Million)

Table 3: Percentage Breakdown of Leading Anti-Psychotics

Brands Value Sales in the World - 2005

Table 4: Percentage Breakdown of Leading Anti-Parkinson's

Disease Brands Value Sales in the World - 2005

Table 5: Sales of Leading Epilepsy Drug Brands in the World -

2005 (In US$ Million)

Table 6: Global CNS Therapeutics Market by Region for the

Period 2007-2015 (Sales in US$ Million)

Table 7: Percentage Breakdown of Global CNS Therapeutics

Market by Region for the Years 2008 & 2012

Table 8: Global Anti-Alzheimer's Drugs Market by Region for

the Period 2007- 2015 (Sales in US$ Million)

Table 9: Percentage Breakdown of Global Anti-Alzheimer's Drugs

Market by Region for the Years 2008 & 2012

Table 10: Global Anti-Parkinson's Drugs Market by Region for

the Period 2007- 2015 (Sales in US$ Million)

Table 11: Percentage Breakdown of Global Anti-Parkinson's

Drugs Market by Region for the Years 2008 & 2012

Table 12: Global Anti-Epilepsy Drugs Market by Region for the

Period 2007-2015 (Sales in US$ Million)

Table 13: Percentage Breakdown of Global Anti-Epilepsy Drugs

Market by Region for the Years 2008 & 2012

Table 14: Global Pain Management Drugs Market by Region for

the Period 2007- 2015 (Sales in US$ Million)

Table 15: Percentage Breakdown of Global Pain Management Drugs

Market by Region for the Years 2008 & 2012

Table 16: Global Anti-Psychotics Drugs Market by Region for

the Period 2007-2015 (Sales in US$ Million)

Table 17: Percentage Breakdown of Global Anti-Psychotics Drugs

Market by Region for the Years 2008 & 2012

Table 18: Global Anti-Depressants Drugs Market by Region for

the Period 2007-2015 (Sales in US$ Million)

Table 19: Percentage Breakdown of Global Anti-Depressants

Drugs Market by Region for the Years 2008 & 2012

Table 20: Global Other CNS Drugs Market by Region for the

Period 2007-2015 (Sales in US$ Million)

Table 21: Percentage Breakdown of Global Other CNS Drugs

Market by Region for the Years 2008 & 2012

Table 22: Percentage Breakdown of Leading Alzheimer Brands

Value Sales in the US - 2005

Table 23: Percentage Breakdown of Leading Anti-Psychotics

Brands Value Sales in the US - 2006

Table 24: Percentage Breakdown of Leading Atypical

Anti-Psychotic Brands Value Sales in the US - 2008

Table 25: Sales of Leading Antidepressant Drug Brands in the

US - 2006 (In US$M)

Table 26: Percentage Breakdown of Leading Anti-Multiple

Sclerosis Drug Brands Value Sales in the US - 2004

Table 27: Percentage Breakdown of Leading ADHD Brands Sales

in the US - 2005

Table 28: Percentage Breakdown of Leading Pain Management

Manufacturers Value Sales in the US - 2007

Table 29: CNS Therapeutics Market by Segment in the US:

2007-2015 (Sales in US$ Million)

Table 30: Percentage Breakdown of CNS Therapeutics Market by

Segment in the US for the Years 2008 & 2012

Table 31: CNS Therapeutics Market by Segment in Canada:

2007-2015 (Sales in US$ Million)

Table 32: Percentage Breakdown of CNS Therapeutics Market by

Segment in Canada for the Years 2008 & 2012

Table 33: Percentage Breakdown of Anti-Psychotics Market

Revenues by Product Class in Europe - 2006

Table 34: Percentage Breakdown of Leading Atypical

Anti-Psychotics Brand Value Sales in Europe - 2004

Table 35: Percentage Breakdown of Leading Anti-Depressant

Brands Value Sales in Europe - 2005

Table 36: Percentage Breakdown of Antidepressants Market

Revenues by Segment in Europe - 2006

Table 37: CNS Therapeutics Market by Region in Europe:

2007-2015 (Sales in US$ Million)

Table 38: Percentage Breakdown of CNS Therapeutics Market by

Region in Europe for the Years 2008 & 2012

Table 39: CNS Therapeutics Market by Segment in Europe:

2007-2015 (Sales in US$ Million)

Table 40: Percentage Breakdown of CNS Therapeutics Market by

Segment in Europe for the Years 2008 & 2012

Table 41: CNS Therapeutics Market by Segment in France:

2007-2015 (Sales in US$ Million)

Table 42: Percentage Breakdown of CNS Therapeutics Market by

Segment in France for the Years 2008 & 2012

Table 43: CNS Therapeutics Market by Segment in Germany:

2007-2015 (Sales in US$ Million)

Table 44: Percentage Breakdown of CNS Therapeutics Market by

Segment in Germany for the Years 2008 & 2012

Table 45: CNS Therapeutics Market by Segment in Italy:

2007-2015 (Sales in US$ Million)

Table 46: Percentage Breakdown of CNS Therapeutics Market by

Segment in Italy for the Years 2008 & 2012

Table 47: CNS Therapeutics Market by Segment in the UK:

2007-2015 (Sales in US$ Million)

Table 48: Percentage Breakdown of CNS Therapeutics Market by

Segment in the UK for the Years 2008 & 2012

Table 49: CNS Therapeutics Market by Segment in Spain:

2007-2015 (Sales in US$ Million)

Table 50: Percentage Breakdown of CNS Therapeutics Market by

Segment in Spain for the Years 2008 & 2012

Table 51: CNS Therapeutics Market by Segment in Rest of

Europe: 2007- 2015 (Sales in US$ Million)

Table 52: Percentage Breakdown of CNS Therapeutics Market by

Segment in Rest of Europe for the Years 2008 & 2012

Table 53: CNS Therapeutics Market by Segment in Asia-Pacific:

2007-2015 (Sales in US$ Million)

Table 54: Percentage Breakdown of CNS Therapeutics Market by

Segment in Asia-Pacific for the Years 2008 & 2012

Table 55: CNS Therapeutics Market by Segment in Latin America:

2007-2015 (Sales in US$ Million)

Table 56: Percentage Breakdown of CNS Therapeutics Market by

Segment in Latin America for the Years 2008 & 2012

Table 57: CNS Therapeutics Market by Segment in Rest of World:

2007- 2015 (Sales in US$ Million)

Table 58: Percentage Breakdown of CNS Therapeutics Market by

Segment in Rest of World for the Years 2008 & 2012

COMPANIES PROFILED

To order this report:

Pharmaceutical Industry: CNS Therapeutics - A World Market Review

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker

21%

more press release views with 

Request a Demo